Jerusalem, Israel: The adjunctive use of high CBD oral extracts is associated with improvements in symptom management in children with autism-related behavioral issues, according to clinical data published online ahead of print in the journal Neurology.
Israeli researchers assessed the use of oral extracts containing a 20 to 1 ratio of CBD to THC in 60 adolescents with autism spectrum disorder.
Following treatment, behavioral outbreaks were “much improved or very much improved in 61 percent of patients.” Nearly half of all patients reported improvement in anxiety and in their communication skills, while 29 percent reported a decrease in disruptive behaviors.
Authors concluded, “This preliminary study supports the feasibility of CBD-based medical cannabis as a promising treatment option for refractory behavioral problems in children with ASD.”
For more information, contact Paul Armentano, NORML Deputy Director, at: firstname.lastname@example.org. Full text of the study, “Cannabis-based medical cannabis in children with autism – A retrospective feasibility study,” appears in Neurology.